SCHEDULE: Andreessen Horowitz Funds Adjust Nautilus Biotech Stake

Several investment funds affiliated with Andreessen Horowitz have reported a reduction in their beneficial ownership of Nautilus Biotechnology, Inc. common stock.

Summary

• This filing is an amendment to a Schedule 13D, indicating a change in beneficial ownership of Nautilus Biotechnology, Inc. common stock by several reporting persons.
• The reporting persons include AH Bio Fund II, L.P., AH Equity Partners Bio II, L.L.C., Andreessen Horowitz LSV Fund II, L.P., AH Equity Partners LSV II, L.L.C., Marc Andreessen, and Benjamin Horowitz.
• As of April 23, 2026, the total outstanding shares of Nautilus Biotechnology, Inc. common stock were reported as 127,078,855.
• AH Bio Fund II, L.P. and AH Equity Partners Bio II, L.L.C. collectively hold 8,366,966 shares, representing 6.6% of the class.
• Andreessen Horowitz LSV Fund II, L.P. and AH Equity Partners LSV II, L.L.C. collectively hold 696,088 shares, representing 0.5% of the class.
• Marc Andreessen and Benjamin Horowitz, as managing members of AH Equity Bio II and AH Equity LSV II, are deemed to have shared voting and dispositive power over a combined 9,063,054 shares, representing 7.1% of the class.
• On June 26, 2026, AH Bio II and AH LSV II sold a combined 3,590,863 shares of common stock at $2.00 per share.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a slightly negative sentiment due to the reported sale of a significant number of shares by major investors, although the overall impact is tempered by the continued substantial ownership by key individuals.

Positives

• The sale of shares was executed at a price of $2.00 per share, indicating a market valuation for the stock.
• The reporting persons maintain significant beneficial ownership, with Marc Andreessen and Benjamin Horowitz still holding a substantial stake (7.1%).

Negatives

• AH Bio Fund II, L.P. and AH LSV II sold a considerable number of shares (3,590,863), reducing their direct holdings.
• The filing is an amendment, suggesting ongoing adjustments to investment positions rather than a static holding.

Risks

• The sale of a significant block of shares by major investors could be interpreted as a lack of confidence or a strategic shift, potentially impacting investor sentiment.
• The filing does not provide specific reasons for the sale, leaving room for speculation about underlying concerns.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Nautilus Biotechnology, Inc. It primarily reports on changes in beneficial ownership by investment entities.

Management Comments

• The filing is an amendment to a previously filed Schedule 13D, indicating ongoing reporting requirements for significant beneficial owners.
• The reporting persons are investment entities and individuals primarily engaged in venture capital and investment management.
• The sale of shares on June 26, 2026, is a key event reported in this amendment.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are crucial for tracking significant ownership changes in public companies, particularly in the technology and biotechnology sectors where venture capital firms like Andreessen Horowitz are active. Such filings can signal shifts in investor sentiment or strategic realignments.

Stakeholder Impact

• Shareholders may react to the sale of shares by major investors, potentially leading to short-term price volatility.
• The continued significant stake held by Marc Andreessen and Benjamin Horowitz suggests ongoing commitment and influence.
• Creditors and suppliers are unlikely to be directly impacted by this ownership change filing.

Next Steps

• Continued monitoring of Nautilus Biotechnology, Inc. for further ownership changes or strategic announcements from the reporting persons.
• Analysis of Nautilus Biotechnology, Inc.'s subsequent financial reports and operational updates to understand the context of the share sales.

Key Dates

Recommendation

The filing indicates a reduction in holdings by some investment entities affiliated with Andreessen Horowitz, but key individuals maintain a significant stake. Without further information on the reasons for the sale or the company's performance, a 'hold' recommendation is prudent, suggesting investors should await more clarity on the company's strategic direction and financial health before making significant buy or sell decisions.

Keywords

Schedule 13D, Nautilus Biotechnology, Andreessen Horowitz, Beneficial Ownership, Stock Sale, SEC Filing, Venture Capital, Investment Management